\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesDear users of the NCP Flanders website,
As of today, the NCP Flanders website has a new look aimed at providing a more user-friendly experience. While the content and services available on the website remain unchanged, the fresh new layout is designed to enhance navigation and accessibility.
Pages specifically related to one of the programmes we advise on can be easily identified by their colour:
The different features such as news, events, info sheets, the video corner and partner searches remain the same and are still easy to find on the top of the page.
We would also like to take this opportunity to invite you check and – if appropriate - update your profile to make sure that you receive information tailored to your specific needs.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has amended the 2025-2027 Digital Europe main work programme. The amendment ("March 2026") can be found on the Commission website alongside the work programme. According to the amendment, the following call topics are part of the next round of calls: Digital solutions for regulatory compliance through data Apply AI: Pil... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
